White Papers
The pricing and market access (P&MA) landscape in China has been rapidly evolving as the country continuously attempts to balance rewarding innovation and sustainability of healthcare funding. China represents a unique and dynamic market archetype for manufacturers especially in terms of P&MA strategies.
China’s aging population (≥60 years) is estimated to exceed 400 million by 2035 driving a significant rise in government healthcare expenditure and medical insurance subsidies in the future. As such, the Chinese government has acknowledged the important…
Read Now
Webinars
Available On Demand
In Part 1 of this webinar series, The Path to Launch, we discussed various pathways and innovative programs to accelerate product launch in China. However, launching a product is only half of the battle. Ensuring optimal access to deliver the treatment to more patients is also critical for commercial success.Join Trinity Life Sciences’ APAC experts for Part 2 as they decode recent key pricing and access dynamics in the China pharmaceutical market and explore what strategies and levers are available to…
Watch Now
Webinars
Available On Demand
What are the latest pricing dynamics from the 2022 NRDL update that manufacturers should learn to succeed in China market access?
The 2022 National Reimbursement Drug List (NRDL) negotiation has recently published the list of successfully negotiated drugs and their post-negotiation prices. The results indicate an improved access environment for new and high-cost innovative therapies.
In this webinar, Trinity Life Sciences’ Value, Access and Pricing experts will provide an in-depth analysis of the 2022 NRDL and key trends from previous…
Watch Now
Webinars
Available On Demand
The pharmaceutical market in China has experienced tremendous growth over the past several decades and is becoming increasingly important. While many life sciences organizations consider China to be a ‘must win’ market, commercial success can be elusive. Despite the large patient base and recent economic and political tailwinds driving the advancement of the healthcare industry, sales for innovative drugs in China are often only a fraction of those in the U.S. The complex and rapidly evolving market dynamics require companies…
Watch Now
Blog
Published March 10, 2023
Executive summary
83 non-traditional Chinese medicines successfully entered the National Reimbursement Drug List (NRDL) for the first time. This is a >20% increase from the 2021 and 2020 NRDL updates, indicating the growing interest of both manufacturers and payers to ensure reimbursement for novel therapies in China.
The percentage of products achieving NRDL inclusion within one year of regulatory approval continues to increase steadily, from 24% in 2020 to 53% in the 2022 update, keeping up the strong momentum of…
Read Now
Blog
Published February 27, 2023
Executive Summary:
The 2023 off-year Drug Price Revisions are the second implementation of the off-year re-pricing approach by the Japanese Ministry of Health, Labor and Welfare (MHLW) and are predicted to result in additional price cuts to 48% of listed products across multiple therapeutic areas.
Although the MHLW continues to maintain a stance of leveraging price revisions to achieve budget savings, other policies (i.e., expansion of Orphan Drug Designation and Price Maintenance Premium revisions) signal an intent to foster and…
Read Now
White Papers
As the market becomes increasingly crowded and budget constraints continue in China, downward pricing pressure to secure National Reimbursement Drug List (NRDL) inclusion remains the top challenge for multinational pharma companies in this market. However, the significant uptake post-NRDL inclusion and broad access offer substantial opportunities for innovative products with clinical differentiation.
In this white paper, Trinity Life Sciences explores the highlights of the 2021 NRDL negotiation; including trends within the oncology, rare disease and chronic disease therapeutic areas…
Read Now
Blog
Published September 6, 2022
Executive Summary
A series of new drug pricing reforms came into effect in Japan in April 2022, to encourage innovation and ensure the transparency and predictability of drug pricing in the future
These include updates to the cost-accounting pricing methodology, an expansion of the scope of the Price Maintenance Premium (PMP), an update to the spillover rule for drug re-pricing and an addition of a new “specific use” premium. Further details are outlined in the graphic below.
Summary of Japan’s…
Read Now
Webinars
Available On Demand
What do pharmaceutical manufacturers need to know to successfully navigate the market access landscape in China through the latest NRDL update?
The access landscape in China is rapidly evolving with important implications for novel medicines. The most recent update of China’s National Reimbursement Drug List (NRDL) in 2021 focused on the expansion of new and high-cost innovative therapies and highlighted the improving access environment for these drugs.
In this webinar, Trinity Life Sciences’ Value, Access and Pricing experts will provide…
Watch Now
Blog
Published August 19, 2021
Executive Summary
While 7 additional rare disease drugs were included on the 2020 NRDL in China, this development comes amid a backdrop of rare disease policy development signaling a move towards multi-channel funding mechanism to support more widespread patient access and maintain sustainability of the NRDL
As such, manufacturers cannot solely rely on NRDL inclusion for their rare disease product market access strategy in China and should consider alternative funding opportunities outside of the NRDL (e.g., provincial critical illness budgets,…
Read Now
